A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA.

Trial Profile

A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Vobarilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Ablynx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jun 2013 24-Week results presented at the 14th Annual Congress of the European League Against Rheumatism.
    • 12 Jun 2013 24-week final analysis of the phase II part of this trial will be presented at the 2013 Annual European Congress of Rheumatology (EULAR), according to an Ablynx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top